Guido Kurz obtained his PhD in Organic Chemistry from TU Munich and Caltech. He is currently the CEO of Oncostellae. In his talk, “Organ selection: JAK inhibitors case study”, Guido will present the approach Oncostellae has taken for the development of one of their oncology projects. In particular, he will describe a strategy for organ targeting.
Guido is a senior manager with over 20 years of international experience in academia as well as industry. He has been involved in several start-ups related to drug development, which has given him valuable insight into the requirements to transfer an early discovery project to the industry.
After a postdoctoral stay at Université de Strasbourg, he joined Pharmacia Corporation in 1998 and then its spin-off Biovitrum in Sweden as a Project Leader working on metabolic diseases. He subsequently took on the roles of Director of Chemistry at Betagenon (2005), Section Head Medchem & Project Leader at the CNIO in Spain (2006), and of Director of Drug Discovery at Oryzon Genomics, where he furthered his experience in drug development (2011). Since 2014, he is the CEO of Oncostellae, a biopharmaceutical company developing novel small-molecule drugs in oncology and inflammatory/autoimmune diseases. They have developed a Jak3/Tyk2 inhibitor that has successfully completed a Phase I clinical trial.